🇺🇸 FDA
Pipeline program

PC14586

PMV-586-101

Phase 2 small_molecule active

Quick answer

PC14586 for Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation is a Phase 2 program (small_molecule) at PMV Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
PMV Pharmaceuticals
Indication
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials